Gliflozins on HF in Regurgitant Rheumatic Heart

NCT06097585 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-10-30

No results posted yet for this study

Summary

The objective of this trial is to detect impact of Gliflozin on patients with heart failure due to reurgitant rheumatic valve disease

Conditions

Interventions

DRUG

SGLT2 inhibitor

case control study in which group will receive SGLT2I and group will not , to detect impact of the drug in changing NYHA class for heart failure and echographic parameter

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Doaa A Fouad, MD · Assiut University

  • Magdy A Algowhary, MD · Assiut University

  • Ahmed G Bakry, MD · South Valley University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-12-01
Completion
2025-04-01

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06097585 on ClinicalTrials.gov